First full approval for BioCryst's peramivir, in Japan
This article was originally published in Scrip
Executive Summary
Japan's regulatory authorities have approved a new drug in what appears to be record time, issuing a full clearance for BioCryst Pharmaceuticals/Shionogi's flu antiviral, peramivir, less than three months after its submission.